Spots Global Cancer Trial Database for polatuzumab vedotin
Every month we try and update this database with for polatuzumab vedotin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | NCT06047080 | Large B-Cell Ly... | Glofitamab Polatuzumab ved... Rituximab Cyclophosphamid... Doxorubicin Prednisone | 18 Years - 80 Years | Hoffmann-La Roche | |
| Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | NCT04884035 | Lymphoma, B-Cel... | CC-220 Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone CC-99282 Polatuzumab ved... Rituximab | 18 Years - | Celgene | |
| A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) | NCT04790903 | Lymphoma, Large... | Venetoclax Polatuzumab Ved... Rituximab Cyclophosphamid... Doxorubicin Prednisone | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT04182204 | Diffuse Large B... | Polatuzumab Ved... Rituximab Gemcitabine Oxaliplatin | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). | NCT04236141 | Diffuse, Large ... | Polatuzumab Ved... Bendamustine Rituximab Placebo | 18 Years - | Hoffmann-La Roche | |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | NCT04659044 | Recurrent B-Cel... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory B-Ce... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Mant... Refractory Marg... Refractory Smal... | Polatuzumab Ved... Rituximab Rituximab and H... Venetoclax | 18 Years - | Academic and Community Cancer Research United | |
| A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma | NCT05954910 | Diffuse Large B... | Polatuzumab Ved... | 18 Years - | Hoffmann-La Roche | |
| A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin | NCT04624893 | Diffuse Large B... | Polatuzumab Ved... | 18 Years - | Jiangsu Cancer Institute & Hospital | |
| A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | NCT01691898 | Follicular Lymp... Diffuse Large B... | Obinutuzumab Pinatuzumab Ved... Polatuzumab Ved... Rituximab | 18 Years - | Genentech, Inc. | |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | NCT05283720 | Non-Hodgkin Lym... | Epcoritamab Lenalidomide Ibrutinib Rituximab Cyclophosphamid... Doxorubicin Hyd... Prednisone Polatuzumab Ved... Venetoclax CC-99282 | 18 Years - | Genmab | |
| A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma | NCT01290549 | Non-Hodgkins Ly... Chronic Lymphoc... | Polatuzumab Ved... Rituximab | 18 Years - | Genentech, Inc. | |
| A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma | NCT01992653 | Lymphoma, Non H... | Cyclophosphamid... Doxorubicin Obinutuzumab Polatuzumab Ved... Prednisolone Prednisone Rituximab | 18 Years - | Genentech, Inc. | |
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT06015880 | Diffuse Large B... High Grade B-Ce... Transformed Ind... | Biospecimen Col... Computed Tomogr... Lenalidomide Mosunetuzumab Polatuzumab Ved... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | NCT05283720 | Non-Hodgkin Lym... | Epcoritamab Lenalidomide Ibrutinib Rituximab Cyclophosphamid... Doxorubicin Hyd... Prednisone Polatuzumab Ved... Venetoclax CC-99282 | 18 Years - | Genmab | |
| A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | NCT05615636 | Hodgkin Lymphom... B-Cell Lymphoma Relapsed B-cell... | Mosunetuzumab Polatuzumab ved... Tafasitamab Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation | NCT06043674 | Chronic Lymphoc... Richter's Trans... | Glofitamab Obinutuzumab Polatuzumab Ved... Atezolizumab Tocilizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma | NCT05006534 | Relapsed Non Ho... Refractory Lymp... | 20 Years - | National Taiwan University Hospital | ||
| A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | NCT03677141 | B-cell Non-Hodg... | Mosunetuzumab Polatuzumab Ved... Rituxumab Cyclophosphamid... Doxorubicin Vincristine Prednisone Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma | NCT05940064 | Diffuse Large B... | Zanubrutinib, P... | 60 Years - | Shanghai Zhongshan Hospital | |
| Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma | NCT05169658 | Non-Hodgkin Lym... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Indolent B-Cell... Marginal Zone L... Recurrent Extra... Refractory Extr... | Mosunetuzumab Obinutuzumab Polatuzumab Ved... | 18 Years - | University of Washington | |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | NCT05633615 | Diffuse Large B... Grade 3b Follic... Primary Mediast... Recurrent Diffu... Refractory Diff... Transformed Fol... Transformed Mar... | Axicabtagene Ci... Biospecimen Col... Computed Tomogr... Cyclophosphamid... Fludarabine Lisocabtagene M... Mosunetuzumab Patient Observa... Polatuzumab Ved... Positron Emissi... Tisagenlecleuce... | 18 Years - | SWOG Cancer Research Network | |
| Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | NCT05455697 | Diffuse Large B... Grade 3b Follic... High Grade B-Ce... | Bone Marrow Bio... Cyclophosphamid... Doxorubicin Prednisone Retifanlimab Rituximab and H... Tafasitamab Vincristine Bone Marrow Asp... Multigated Acqu... Fludeoxyglucose... Positron Emissi... Computed Tomogr... Biospecimen Col... Polatuzumab Ved... | 18 Years - | University of Washington | |
| A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL | NCT03467373 | B-Cell Lymphoma Non-Hodgkin Lym... | Glofitamab Obinutuzumab (G... Rituximab (R) Tocilizumab Cyclophosphamid... Doxorubicin Vincristine Prednisone Polatuzumab ved... | 18 Years - | Hoffmann-La Roche | |
| A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma | NCT06071871 | Large B-cell Ly... | Glofitamab Polatuzumab ved... Obinutuzumab | 18 Years - | University College, London | |
| Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | NCT04607772 | Relapsed or Ref... | Selinexor Rituximab Bendamustine Polatuzumab Ved... Ibrutinib Lenalidomide Tafasitamab Venetoclax Gemcitabine Oxaliplatin | 18 Years - | Karyopharm Therapeutics Inc | |
| Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma | NCT05498220 | Diffuse Large B... | Polatuzumab ved... Rituximab Hyaluronidase Gemcitabine Cisplatin Dexamethasone GCSF | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | NCT05615636 | Hodgkin Lymphom... B-Cell Lymphoma Relapsed B-cell... | Mosunetuzumab Polatuzumab ved... Tafasitamab Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | NCT02600897 | Relapsed or Ref... | Lenalidomide Obinutuzumab Polatuzumab Ved... Rituximab | 18 Years - | Hoffmann-La Roche | |
| An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | NCT06047080 | Large B-Cell Ly... | Glofitamab Polatuzumab ved... Rituximab Cyclophosphamid... Doxorubicin Prednisone | 18 Years - 80 Years | Hoffmann-La Roche | |
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT06015880 | Diffuse Large B... High Grade B-Ce... Transformed Ind... | Biospecimen Col... Computed Tomogr... Lenalidomide Mosunetuzumab Polatuzumab Ved... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma | NCT03274492 | Diffuse Large B... | Polatuzumab Ved... Rituximab Cyclophosphamid... Doxorubicin Vincristine Vincristine Pla... Prednisone Polatuzumab ved... | 18 Years - 80 Years | Hoffmann-La Roche | |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | NCT04970901 | B-Cell Non-Hodg... Relapsed B-Cell... Refractory B-Ce... | Loncastuximab T... Polatuzumab Ved... Glofitamab Mosunetuzumab Obinutuzumab | 18 Years - | ADC Therapeutics S.A. | |
| Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT04665765 | Diffuse Large B... Recurrent Diffu... Recurrent Prima... Recurrent Trans... Refractory Diff... Refractory Prim... Refractory Tran... | Carboplatin Etoposide Ifosfamide Polatuzumab Ved... Rituximab | 18 Years - | City of Hope Medical Center | |
| An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | NCT03533283 | Non-Hodgkins Ly... | Glofitamab Atezolizumab Obinutuzumab Tocilizumab Polatuzumab Ved... 89Zr-Df-IAB22M2... | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | NCT04970901 | B-Cell Non-Hodg... Relapsed B-Cell... Refractory B-Ce... | Loncastuximab T... Polatuzumab Ved... Glofitamab Mosunetuzumab Obinutuzumab | 18 Years - | ADC Therapeutics S.A. | |
| Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | NCT04491370 | B-cell Lymphoma Burkitt Lymphom... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Transformed Non... Richter Syndrom... Hodgkin Lymphom... | Polatuzumab ved... | 12 Years - 70 Years | New York Medical College | |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | NCT04970901 | B-Cell Non-Hodg... Relapsed B-Cell... Refractory B-Ce... | Loncastuximab T... Polatuzumab Ved... Glofitamab Mosunetuzumab Obinutuzumab | 18 Years - | ADC Therapeutics S.A. | |
| A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma | NCT03274492 | Diffuse Large B... | Polatuzumab Ved... Rituximab Cyclophosphamid... Doxorubicin Vincristine Vincristine Pla... Prednisone Polatuzumab ved... | 18 Years - 80 Years | Hoffmann-La Roche | |
| A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | NCT05171647 | Non-Hodgkin Lym... | Mosunetuzumab Polatuzumab ved... Tocilizumab Rituximab Gemcitabine Oxaliplatin | 18 Years - | Hoffmann-La Roche | |
| Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma | NCT03677154 | Diffuse Large B... | Mosunetuzumab I... Mosunetuzumab S... Polatuzumab Ved... Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP | NCT05798156 | Lymphoma, Large... | Glofitamab Rituximab Obinutuzumab Polatuzumab ved... | 61 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | NCT04594798 | DLBCL Lymphoma, B-Cel... | Polatuzumab ved... Rituximab Cyclophosphamid... Doxorubicin Prednisone | 75 Years - | University of Rochester | |
| Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | NCT04491370 | B-cell Lymphoma Burkitt Lymphom... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Transformed Non... Richter Syndrom... Hodgkin Lymphom... | Polatuzumab ved... | 12 Years - 70 Years | New York Medical College | |
| Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | NCT04884035 | Lymphoma, B-Cel... | CC-220 Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone CC-99282 Polatuzumab ved... Rituximab | 18 Years - | Celgene | |
| Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma | NCT05498220 | Diffuse Large B... | Polatuzumab ved... Rituximab Hyaluronidase Gemcitabine Cisplatin Dexamethasone GCSF | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | NCT04607772 | Relapsed or Ref... | Selinexor Rituximab Bendamustine Polatuzumab Ved... Ibrutinib Lenalidomide Tafasitamab Venetoclax Gemcitabine Oxaliplatin | 18 Years - | Karyopharm Therapeutics Inc | |
| Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | NCT05455697 | Diffuse Large B... Grade 3b Follic... High Grade B-Ce... | Bone Marrow Bio... Cyclophosphamid... Doxorubicin Prednisone Retifanlimab Rituximab and H... Tafasitamab Vincristine Bone Marrow Asp... Multigated Acqu... Fludeoxyglucose... Positron Emissi... Computed Tomogr... Biospecimen Col... Polatuzumab Ved... | 18 Years - | University of Washington | |
| A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma | NCT01290549 | Non-Hodgkins Ly... Chronic Lymphoc... | Polatuzumab Ved... Rituximab | 18 Years - | Genentech, Inc. | |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | NCT04659044 | Recurrent B-Cel... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory B-Ce... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Mant... Refractory Marg... Refractory Smal... | Polatuzumab Ved... Rituximab Rituximab and H... Venetoclax | 18 Years - | Academic and Community Cancer Research United | |
| A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT04182204 | Diffuse Large B... | Polatuzumab Ved... Rituximab Gemcitabine Oxaliplatin | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT04182204 | Diffuse Large B... | Polatuzumab Ved... Rituximab Gemcitabine Oxaliplatin | 18 Years - | Hoffmann-La Roche | |
| Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | NCT04679012 | Richter Syndrom... Chronic Lymphoc... | Polatuzumab Ved... Rituximab Etoposide Prednisone Cyclophosphamid... Hydroxydaunomyc... | 18 Years - | Weill Medical College of Cornell University | |
| A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma | NCT03671018 | B-cell Non-Hodg... | Mosunetuzumab (... Mosunetuzumab (... Polatuzumab ved... Tocilizumab Rituximab | 18 Years - | Hoffmann-La Roche | |
| Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma | NCT05410418 | Lymphoma, Folli... Follicular Lymp... | Mosunetuzumab Polatuzumab ved... | 18 Years - | Washington University School of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
